Disc Medicine Opco : Reports Full Year 2022 Financial Result

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic... | March 31, 2023

Related Keywords

China , United States , American , Suzanne Messere , Arix Bioscience , John Quisel , European Committee For Orphan Medical Products , Novo Holdings , Nasdaq , European Hematology Association Annual Congress , Atlas Venture , Disc Medicine Inc , Development Expenses , Verge Scientific Communications , Bain Capital Life Sciences , Drug Administration , American Society Of Hematology Annual Meeting , Exchange Commission , Disc Medicine Reports Full Year , Provides Business , Gemini Therapeutics , Chief Executive Officer , Anticipated Milestones , Heme Synthesis Modulator , Orphan Drug Designation , European Committee , Orphan Medical Products , Orphan Designation , Diamond Blackfan Anemia , Anti Hemojuvelin Antibody , Hepcidin Suppression , American Society , Hematology Annual , Hepcidin Induction , Transmembrane Serine Protease , Mabwell Therapeutics , Greater China , Access Biotechnology , Rock Springs Capital , Janus Henderson , Bain Capital Life , Administrative Expenses , Private Securities Litigation Reform Act , Annual Report , Ended December , Convertible Preferred Stock , Stockholder Equity , Disc Medicine Opco Inc Stock Exchange , News , Information , Press Release , Cisc , Iopharmaceutical , Company , Ocused , N , The , End , Ommercialization , F , Novel , Treatments , Or , Patients , Suffering , Rom , Erious Iron Us2546041011 ,